Biological products and technologies developer Microbix Biosytstems Inc., today said that it has increased by 500 per cent the company’s capacity for antigen manufacturing following a series of upgrades.
The company announced it is now scaling-up its largest-selling product into multiple bioreactors. Production is going from one production-oriented bioreactor to six and transferring the process from development to manufacturing.
All six units have been delivered and will enter production in early 2018. A multi-month production cycle means that the full benefit of the bioreactors will be realized in the fiscal year ending September 2019.
Microbix is also enhancing its downstream processing capacity, including a doubling of the power supply to its facility.
The company’s revenues come mainly from sales of its antigens as critical components for makers of tests that diagnose infectious diseases.
Antigens are traditionally produced in thousands of “roller bottles,” a method requiring considerable space, material and labour. However, Microbix has developed a production process using bioreactors, which promise better process control and yield, with reduced space, material, and labour per unit of product.
“The use of bioreactors is necessary to increase sales and profitability and to realize the full potential of our antigens business,” said Cameron Groome, president and of Microbix. “Our adoption of bioreactors for production and increasing our downstream processing capacity is evidence that our growth initiatives are fully underway.”
The recent changes will enable Microbix to meet increasing demand for its products, by way of increased bioreactor capacity said Phil Casselli, senior vice-president of sales and business development at MIcrobix. The changes will allow the company to reallocate facility space for ore production of other antigens and enhanced downstream processing capacity.
“Increasing our production capacity should enable us to fulfill our customers’ growing need for high-quality antigens,” he said.